bluebird bio, Inc. (0HOH.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Al 03:47PM BST. Mercato aperto.
| Chiusura precedente | 3,36 |
| Aperto | 3,39 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 3,31 - 3,39 |
| Intervallo di 52 settimane | 3,31 - 3,39 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 10,064B |
| Beta (5 anni mensile) | 1,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -10,43 |
| Prossima data utili | 08 ago 2022 - 12 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil
© 2022 Yahoo. Tutti i diritti riservati.
